Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
NCT02349412
Clinical Trial Information
Trial Number: NCT02349412 (ClinicalTrials.gov)
Disease Type:
- Gastrointestinal Neoplasm - Gastroesophageal Cancer
- Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
- Gastrointestinal Neoplasm - Pancreatic Cancer (excluding Islets)
- Lung, Mediastinal and Pleural Neoplasm - Mesothelioma
- Lung, Mediastinal and Pleural Neoplasm - Non-Small Cell Lung Cancer
- Lung, Mediastinal and Pleural Neoplasm - Small Cell Lung Cancer
Trial Title:
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Study ID:
A221303
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02349412-D9 | Dataset NCT02349412-D9-Dataset.csv (nctn_supp_table3) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Supplementary Table 3 from the manuscript. |
| NCT02349412-D8 | Dataset NCT02349412-D8-Dataset.csv (nctn_supp_table2) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Supplementary Table 2 from the manuscript. |
| NCT02349412-D7 | Dataset NCT02349412-D7-Dataset.csv (nctn_supp_table1) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Supplementary Table 1 from the manuscript. |
| NCT02349412-D6 | Dataset NCT02349412-D6-Dataset.csv (nctn_fig2) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Figure 2 from the manuscript. |
| NCT02349412-D5 | Dataset NCT02349412-D5-Dataset.csv (nctn_table4) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Table 4 from the manuscript. |
| NCT02349412-D4 | Dataset NCT02349412-D4-Dataset.csv (nctn_table3) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Table 3 from the manuscript. |
| NCT02349412-D3 | Dataset NCT02349412-D3-Dataset.csv (nctn_table2) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Table 2 from the manuscript. |
| NCT02349412-D2 | Dataset NCT02349412-D2-Dataset.csv (nctn_table1) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce Table 1 (Baseline characteristics) from the manuscript. |
| NCT02349412-D1 | Dataset NCT02349412-D1-Dataset.csv (nctn_consort) is one of 9 datasets associated with PubMed ID 32031887. This dataset contains information that will allow you to reproduce the consort diagram. |
NCT01015833
Clinical Trial Information
Trial Number: NCT01015833 (ClinicalTrials.gov)
Disease Type:
- Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
Trial Title:
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Study ID:
CALGB-80802
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01015833-D1 | Dataset NCT01015833-D1-Dataset.csv (nctn_d1) is the only dataset associated with PubMed ID 31486832. This dataset contains the information for the entire primary analysis. |
NCT00980460
Clinical Trial Information
Trial Number: NCT00980460 (ClinicalTrials.gov)
Disease Type:
- Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
Trial Title:
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Study ID:
AHEP0731
Images are available?:
Yes
Imaging data can be requested via the NCTN/NCORP Data Archive. To view imaging data details before requesting data here, visit:
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00980460-D11 | There are two data submissions associated with PMID 37073741: NCT00980460-D10 through -D11. This dataset, NCT00980460-D11, provides all grade 3 and 4 adverse events while on protocol therapy for the 36 eligible high-risk hepatoblastoma patients enrolled on AHEP0731 (Supplemental Table 3. Selected Grade 3 and 4 Toxicities) as well as selected grade 3 and 4 adverse events while on protocol therapy (Table 4. Selected grade 3 and 4 toxicities for patients treated with vincristine/irinotecan/temsirolimus upfront window therapy followed by cisplatin/5-fluorouracil/vincristine/doxorubicin.). The number of rows per patient is dependent on the number of adverse events submitted. |
| NCT00980460-D10 | There are two data submissions associated with PMID 37073741: NCT00980460-D10 through -D11. This dataset, NCT00980460-D10, provides the information of baseline characteristics, α-fetoprotein levels, α-fetoprotein and RECIST response, as well as details on recurrent disease, metastatic disease, and surgery for the 40 high-risk hepatoblastoma patients who were enrolled on AHEP0731. Tumor histologic information and pretext classification from central review are also included as well as outcome data as reported in the manuscript. It is used to generate Table 1. Characteristics of eligible patients with high-risk hepatoblastoma treated with upfront vincristine/irinotecan/temsirolimus window therapy, Table 2. Response of patients to upfront vincristine/irinotecan/temsirolimus window therapy, Table 3. Surgical outcomes for patients treated with vincristine/irinotecan/temsirolimus upfront window therapy, Figure 1. Alpha-fetoprotein (AFP) decline after two cycles of VIT (vincristine/irinotecan/temsirolimus) therapy., and Figure 2. Event-free and overall survival of patients with high-risk hepatoblastoma treated with VIT (vincristine/irinotecan/temsirolimus). There are 40 patients in this data file. There is one row for each patient. |
| NCT00980460-D9 | NCT00980460-D9 Dataset Description: NCT00980460 – There is one data submission associated with PMID 35810020: NCT00980460-D9 provides the information for the 8 very low-risk hepatoblastoma patients who were enrolled on AHEP0731. The dataset provides the information of baseline characteristics, α-fetoprotein levels, pretext group, vascular involvement, surgical details and tumor histology from local and central review, as well as outcome data as reported in the manuscript. It is used to generate all the tables in the manuscript, (Table 1. Patient Characteristics for Children with Very Low-Risk Hepatoblastoma and Table 2. Clinical and Surgical Traits for Children with Very Low-Risk Hepatoblastoma), and Figure 2. Event-free Survival and Overall Survival of Patients with Very Low Risk Hepatoblastoma Resected at Diagnosis. There are 8 patients in this data file. There is one row for each patient. |
| NCT00980460-D8 | There are three data submissions associated with PMID 34762296: NCT00980460-D6 through -D8. This dataset, NCT00980460-D8, provides the information for adverse events recorded for all eligible intermediate-risk patients enrolled on AHEP0731, up to 02/10/2020. It contains data on Table 2 (Toxicities (Grade 3, 4, and 5) of Patients with Intermediate-risk Hepatoblastoma), and the information on adverse events and toxicities in the Results section of the manuscript. There are 723 observations, one for each toxicity type per patient per cycle, included in this data file. The number of rows per patient is dependent on the number of adverse events submitted. |
| NCT00980460-D7 | There are three data submissions associated with PMID 34762296: NCT00980460-D6 through -D8. This dataset, NCT00980460-D7, provides the information for all eligible intermediate-risk patients enrolled on AHEP0731, up to 02/10/2020. It contains data on the mean percentage of the target dose delivered for chemotherapy. There are 195 observations in this data file, multiple rows per patient, with proportion of target dose delivered for cisplatin, 5-FU, doxorubicin and vincristine. |
| NCT00980460-D6 | There are three data submissions associated with PMID 34762296: NCT00980460-D6 through -D8. This dataset, NCT00980460-D6, provides the information for all intermediate-risk patients who were enrolled on AHEP0731, up to 02/10/2020, both eligible and ineligible. It contains data presented in Figure 1 (the consort diagram), Figure 2 (Event-Free and Overall Survival of Patients with Unresectable non-Metastatic Hepatoblastoma), Table 1 (Patient Demographics for Patients with Intermediate-risk Hepatoblastoma), and the baseline characteristics and all primary analyses reported in the manuscript. There is one row per patient. There are 105 patients in this data file. |
| NCT00980460-D5 | This dataset provides the information for the specific toxicities that occurred during protocol therapy. Evaluable patients are defined in the main data set (analysis01 = 1). There is one row per patient/toxicity term. Each row has the maximum grade of the particular toxicity term observed during the patient’s protocol treatment. |
| NCT00980460-D4 | This dataset provides the information for baseline characteristics, disease stage, surgical outcome event-free survival and overall survival. Information is only provided for eligible patients (analysis01 = 1). There is one row per patient. |
| NCT00980460-D3 | NCT00980460-D3-Dataset (Adverse Events specifically nausea and neuropathy during cycles 1-2) This dataset provides the information for nausea and neuropathy that occurred during cycles 1 and 2 for evaluable patients. Evaluable patients are defined in the main data set (analysiset = 1). There is one row per patient. |
| NCT00980460-D2 | NCT00980460-D2-Dataset (Adverse Events during all cycles 1-10) This dataset provides the information for the specific toxicities that occurred during cycles 1 through 10 for evaluable patients. Evaluable patients are defined in the main data set (analysiset = 1). There are multiple rows per patient depending on whether they had multiple cycles submitted. |
NCT00716976
Clinical Trial Information
Trial Number: NCT00716976 (ClinicalTrials.gov)
Disease Type:
- Bone Neoplasm - Osteosarcoma
- CNS Neoplasm (Primary Tumor) - Embryonal Tumors
- CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
- Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer
- Germ Cell Neoplasm - Miscellaneous
- Miscellaneous Neoplasm - Solid Tumor
Trial Title:
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children
Study ID:
ACCL0431
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00716976-D3 | NCT00716976-D3 One row for each of the 194 serious adverse events detailed on manuscript page 69. These events are reported through the National Cancer Institute, Cancer Therapy Evaluation Program, Adverse Event Reporting System (CTEP-AERS). |
| NCT00716976-D2 | NCT00716976-D2 These data provide the incidence of toxicities. There is one record per patient-cycle. analysiset2=1 for rows included in Table 3 construction. analysiset3=1 for rows included in Table 4 construction. |
| NCT00716976-D1 | NCT00716976-D1 There is one row for each patient enrolled. The first 14 variables are used to make Figure 1. Patients considered for analysis of study outcomes have the variable analysiset1=1. Variables 15-50 provide patient characteristics (Table 1), outcome (Figures 2 and 3) and hearing loss comparisons (Table 2). |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®